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Abstract: Although several pharmacological options to treat depression are currently available,
approximately one third of patients who receive antidepressant medications do not respond
adequately or achieve a complete remission. Thus, novel strategies are needed to successfully address
those who did not respond, or partially respond, to available antidepressant pharmacotherapy.
Research findings revealed that the opioid system is significantly involved in the regulation of mood
and incentives salience and may be an appropriate target for novel therapeutic agents. The present
study aimed to systematically review the current literature about the use of buprenorphine (BUP)
for major depression, treatment-resistant depression (TRD), non-suicidal self-injury (NSSI) behavior,
and suicidal behavior. We investigated Pubmed and Scopus databases using the following
keywords: “buprenorphine AND depression”, “buprenorphine AND treatment resistant depression”,
“buprenorphine AND suicid*”, “buprenorphine AND refractory depression”. Several evidence
demonstrate that, at low doses, BUP is an efficacious, well-tolerated, and safe option in reducing
depressive symptoms, serious suicidal ideation, and NSSI, even in patients with TRD. However,
more studies are needed to evaluate the long-term effects, and relative efficacy of specific combinations
(e.g., BUP + samidorphan (BUP/SAM), BUP + naloxone (BUP/NAL), BUP + naltrexone) over BUP
monotherapy or adjunctive BUP treatment with standard antidepressants, as well as to obtain more
uniform guidance about the optimal BUP dosing interval.
Keywords: endocannabinoid system; buprenorphine; treatment-resistant depression; major
depression; suicidal behavior
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1. Introduction
1.1. The Impact of Major Depression and Treatment Resistant Depression Worldwide
According to WHO estimation, more than 320 million people are affected by major depression
worldwide, with the prevalence of this disabling condition that is increased by 18.4% from 2005 to
2015 [1]. Depression may be considered the second leading cause of disability (7.5% of all Years Lived
with Disability—YLD) [2]. Although the burden and disability related to this condition, the STAR*D
study clearly showed that about 50% of patients with major depressive disorder (MDD) will experience
a response with the first treatment [3] but only 30% achieve a complete remission and the remaining
percentage will need to undergo several additional treatment trials in order to improve response [4].
These remission rates are lower in treatment-resistant depression (TRD) [5] which is associated with a
higher risk of recurrence, substance abuse, and suicidal behavior [6,7]. Furthermore, MDD frequently
appears to exert neuro-progressive clinical characteristics, with recurring episodes of increasing
severity, reduced therapeutic response [8], and persistence of residual symptoms which commonly
predict a poorer outcome [9]. In this context, it is crucial to obtain a complete remission or—at
least—manage and appropriately treat depressive residual symptoms in order to reduce the risk of
relapses, associated psychosocial impairment, and suicidal attempts [6,10].
Importantly, while suicidal behavior occurs in the presence of any psychiatric condition,
consistent studies repeatedly showed that suicide is most common in subjects with major mood
disorders (MDD and bipolar disorder) [11]. In 2015, suicide across all ages entered the top 20 leading
causes of death—accounting as the most relevant cause of death for 1.5% of all deaths worldwide—and
the second one among 15–29 years old after accidents [2]. These numbers are underestimated in case
we take into account those who made nonfatal suicide attempts and those who experienced suicidal
ideation or engaged in non-suicidal-self-injury-behavior (NSSI) [2].
NSSI was recently added to the Diagnostic and Statistical Manual of Mental Disorders—5th
edition (DSM 5), and it is commonly defined as the intentional, direct destruction of body tissue
without suicidal intent [12]. It has a prevalence of 4% in the general population and up to 21%
in clinical samples [13]; this behavior doubles the expected all-cause mortality rate (risk of death
from suicide, accidents, and natural causes) of subjects who engage in it compared with the general
population [14]. Endogenous opioid system seems to be involved in the etiology of NSSI behavior
too, as suggested by the efficacy of opioid antagonists (i.e., naloxone and naltrexone) in reducing
these behaviors. Other effective treatment options for NSSI are needed, though, in particular for
non-responders [15].
1.2. Psychoacvtive Treatments for Major Affective Disorders: A Brief Overview
The use of Papaver somniferum derivatives as a cure for various ills goes back to prehistory;
opioid cures for melancholia was proposed in the early 1900s, with the use of this compound—although
seemingly effective—which has been slowed by its high addictive properties [16]. In the 1950s,
the discovery of euphoric properties of isoniazid—a monoamine oxidase inhibitor’s (MAOi)
progenitor—and imipramine—from which the tricyclics derive—gradually reduced the importance of
opiates [17], and currently selective serotonin reuptake inhibitors (SSRIs) are considered the standard
first-line treatment for major depression [18,19]. Unfortunately, as we stated above, SSRIs are effective
in only 40–50% of patients [20]; thus, currently, opioids are being re-investigated in order to create new
therapeutic options for major depression with a reduced abuse potential, e.g., using the combination
with compounds such as naloxone or samidorphan [21,22].
From a neurobiological point of view, opioids play a crucial role in pain processing,
stress responses, respiration, gastrointestinal transit, and the endocrine system—in particular,
the hypothalamus-pituitary-adrenal gland (HPA) axis—and immune functions [23,24], and their
dysregulation exerts an important role in attachment, loss, anhedonia, and MDD itself [16,25].
The endogenous opioid system is composed of three different G-protein coupled receptors
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(GPCRs)—µ-, δ-, and κ-opioids receptors (MORs, DORs, and KORs, respectively)—that are linked with
a family of endogenous opioid peptides known as β-endorphin, enkephalins, and dynorphins [26].
These receptors are widespread in central and peripheral nervous system, with a high density in limbic
areas that explains, at least partially, their role in reward processing and mood control, and supports
their use to treat emotional dysfunction [27]. These pharmacological options have been hypothesized
to modulate BDNF activity and enhance neurogenesis in the hippocampus as well [28].
Preclinical research with constitutive knockout (KO) mice showed that MORs, DORs and KORs
have distinct role over mood-related processes [29]. In particular MOR—in which BUP acts as a partial
agonist—is a key molecular player in the reward processing circuit contributing to recreational drug
use and addictive behaviors. It has been reported that MOR activation in the dorsal raphe nucleus
(DRN) and ventral tegmental area (VTA) by local GABAergic interneurons disinhibits both 5-HT and
DA neurons, but inhibits noradrenergic neurons [26,30,31]. The MOR-mediated mechanism of mood
control is more complex than described above; in fact, some studies showed even a paradoxical
depressive-like potential of MOR according to the evidence that two groups of MOR KO mice
appeared to have decreased anxiety- and depressive-like behaviors [32]. DOR—that is antagonized
by BUP—together with encephalin, seems to have a mood-enhancing activity, but it is not clear
how it regulates the reward process [33]. KOR—antagonized by BUP, too—exhibits, in contrast to
MOR activity, a major anti-reward role being able to reduce reward tonically [34]. Interestingly,
this type of activity is potentiated by different stressors and may play a role in various stress-induced
psychopathological conditions [24]. The dynorphin/KOR system, through the action on DA neurons
in the nucleus accumbens (NAc), may be linked to depressive-like behaviors [24].
1.3. The Potential of Buprenorphine
Pharmacodynamic notions: BUP is a MOR partial agonist and a KOR/DOR antagonist; it binds
with a high affinity to MOR and KOR, and it binds with a lower affinity to DOR [35].
By a pharmacokinetic point of view, BUP, due to the first-pass effect, has a low oral bioavailability
and, therefore, a sublingual administration (bioavailability of almost 51%) seems more useful [36].
The peak serum concentration after multiple doses of BUP is reached in 1 to 2 h, approximately,
while the time needed to reach the maximum concentration (Tmax) after a single dose, is about 40 min
to 3.5 h [37].
Concerning metabolism and elimination, BUP undergoes hepatic metabolism—primarily by
CYP450-3A4 and CYP 2C8—and, after N-dealkylation, it is transformed in nor-BUP [38]. These two
compounds are then glucuronized [39], and later excreted by the renal and biliary route. About 70% of
the drug is fecally excreted; however, it is re-absorbed as free BUP, and nor-BUP [39].
As mentioned previously, depression is a high-burden disease, in terms of YLD, with a high
prevalence of recurrence and clinicians have to commonly face a relevant issue in its pharmacological
treatment with typical drugs that impact on monoamine system. Given this background, it is important
to find other compounds that act on different systems; BUP is a synthetic opiate that has shown,
in both animal models and human studies, interesting antidepressant-like effects, and a reduction of
self-injurious behavior and suicidal behavior [40].
Thus, the present report is mainly aimed to perform a systematic review of the current literature
about BUP in major depression, TRD, NSSI, and suicidal behavior.
2. Results
2.1. Study Sample
The searches in Pubmed and Scopus databases revealed, after the removal of duplicates, a
total of 2478 potentially relevant articles about BUP and depression (e.g., unipolar and bipolar
depression, TRD). Overall, the search generated 478 articles in Pubmed and 2000 in Scopus, respectively.
One additional record was identified through other sources. After the removal of duplicates, a total of
Int. J. Mol. Sci. 2018, 19, 2410 4 of 20
2078 potentially relevant articles about BUP and depression (e.g., unipolar and bipolar depression,
TRD) remained. Of these, 2068 were excluded because they were without an abstract or had an abstract
that did not explicitly mention depression or suicidal ideation, or were on animal studies, or were
written in a non-English language. Thus, 10 studies met our inclusion criteria and were included in the
present review. Figure 1 summarizes the main results of the search strategy (identification, screening,
eligibility, and inclusion process) used for selecting studies.
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Concerning BUP and suicidal behavior (e.g., suicidal ideation, suicidal thoughts, suicide attempts
or NSSI), the search generated 273 articles (65 articles in Pubmed and 208 in Scopus). One additional
record was identified through other sources. After the removal of duplicates, a total of 214 potentially
relevant articles remained. Of these, 210 were excluded because they were without an abstract or had
an abstract that did not explicitly mention suicidal behavior. Thus, four studies met our inclusion
criteria and were included in the present review. Figure 2 summarizes the main findings of the search
strategy (identification, screening, eligibility, and inclusion process) used for selecting studies.
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Regarding the efficacy of BUP on suicidal ideation, in addition to the Striebel report, two other
studies were added—one randomized, double-blind, and placebo-controlled clinical trial [51], and one
case report [52]—for a total of 90 patients having heterogeneous diagnoses (i.e., Borderline Personality
Disorder, Major Depressive Disorder, Adjustment Disorders, Eating Disorders, Post-Traumatic Stress
Disorder, Substance-Induced Depressive Disorder), but all with clinically significant suicidal ideation.
Only one clinical case study about NSSI behavior was found [53]: it included 6 patients with self-injury
behavior who were treated with BUP.
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2.3. Study Quality Assessment
According to our quality score system, the mean score of the seven studies regarding BUP and
TRD was 4.7; the mean score of the four studies on opiate-dependent patients was 3.5; the mean score
of the three studies about BUP and suicide ideation was 3; the mean score of the Norelli et al. study
about NSSI was 2, respectively. Specifically, the mean score of the three case-report studies concerning
BUP and depression/suicidal behavior included in the present review was 2 while the mean score of
the ten controlled studies concerning BUP and depression/suicidal behavior included in the present
review was 5.
Overall, most of the included studies (N = 8) were of moderate quality, one was of good quality,
and four of low quality. The most relevant findings of the thirteen included studies are reported below.
The three case-report studies concerning BUP and depression/suicidal behavior were of low quality
while the ten controlled studies concerning BUP and depression/suicidal behavior included in the
present review were of moderate quality.
2.4. Studies Description
Three case-reports were included in this review: the studies of Striebel and Kalapatapu [47],
Ahmadi et al. [52], and Norelli et al. [53]. Striebel and Kalapatapu [47] described the case of a 61-year
old women affected by chronic-opiate dependent back pain and depression who was treated with
16 mg/4 mg of BUP/naloxone daily. This drug combination was associated with no craving, managed
her pain, and improved her mood, arresting suicidal ideation. Moreover, Ahmadi and colleagues [52]
investigated a patient with suicidal ideation and substance-induced depression: the 25-year old man
was successfully treated with a 8 mg single dose of sublingual BUP as an adjunctive treatment to
olanzapine and valproate 20 and 400 mg daily doses, respectively. Furthermore, Norelli et al. [53]
described a case series including six psychiatric inpatients with severe, treatment refractory NSSI
on which BUP has been administered—in different doses—in combination with other therapies
(e.g., antipsychotic medications including clozapine, antidepressants, mood stabilizers including
lithium, valproate, and carbamazepine, benzodiazepines, α-adrenergic and β-blockers, and the
opiate antagonist naltrexone). Overall, six patients showed an improvement in NSSI behavior.
These three case reports demonstrate a relevant efficacy of BUP treatment on suicidal ideation,
depression symptoms, and NSSI.
Then, the three observational-prospective studies conducted by Nyhuis and colleagues [46],
Kosten et al. [48], and Gerra et al. [50] were assessed. Nyhuis and colleagues [46] observed in
six nonpsychotic TRD patients an improvement of depressive symptoms after seven days of
BUP treatment, as a monotherapy, at a medium dose of 1.2 mg/day. Kosten et al. [48] and
Gerra et al. [50] assessed depressive symptoms in substance dependent patients (40 and 60 subjects,
respectively). Gerra and colleagues [50] observed a greater reduction of irritability, depression,
tiredness, and psychosomatic symptoms in the BUP + naltrexone group vs. naltrexone alone group
after 12 weeks of treatment. Kosten et al. reported antidepressant effects during one month of
treatment in opioid dependent patients switched to BUP from methadone or treated directly with BUP
(mean sublingual daily BUP dose of 3.2 mg).
In this review, we also evaluated two non-controlled, open label clinical trials (Bodkin et al. [42]
and Karp et al. [43]). Bodkin [42] treated 10 TRD subjects with BUP, according to tolerance and clinical
benefits, with a maximum daily dosage of 1.8 mg. After four to six weeks, seven patients showed
clinically striking improvements in both subjective and objective measures of depression. Similarly,
Karp et al. [43] found an improvement of depressive symptoms in 15 TRD patients after BUP treatment
(average maximum dose = 0.7 mg/day), with the most relevant decline observed in the first three
weeks. Moreover, Karp et al. showed an important improvement in executive functions and learning
from pre- to post-treatment.
We then assessed five randomized, double-blind, placebo-controlled clinical trials (the studies
of Emrich et al. [41], Dean et al. [49], Ehrich and colleagues [44], Yovell et al. [51], and
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Fava and colleagues [45]). Emrich et al. [41], through a pilot ABA study conducted in TRD
patients treated with BUP, found a slight to strong reduction of depressive symptoms. Dean and
colleagues [49], comparing BUP and methadone treatments on a group of heroin-dependent patients,
reported improvements in depressive symptoms in all subjects, with no significant differences between
the groups. Ehrich and colleagues [44] evaluated the efficacy of two different BUP/samidorphan
combinations (8:1 dose-ratio = BUP/SAM 2 mg/0.25 mg for 3 days and BUP/SAM 4 mg/0.5 mg for four
days; BUP:SAM 1:1 dose ratio = 4 mg/4 mg, and BUP/SAM 8 mg/8 mg over the same time periods),
and observed the greatest antidepressant effects in the 1:1 ratio group, which resulted associated with
the maximal blockade of opioid effects. Additionally, Fava and colleagues [45] evaluated the efficacy
of this combination in MDD patients, in a four-week prospective study using BUP/SAM 2 mg/2 mg
(the 2/2 dosage group) and BUP/SAM 8 mg/8 mg (the 8/8 dosage group), respectively. They found
the greatest depression reduction in the 2/2 dosage group, while the improvement did not achieve
statistical significance in the 8/8 dosage group.
Finally, Yovell et al. [51] observed a significant decrease in suicidal ideation in severely suicidal
patients treated with an ultra-low-dose (mean final dosage = 0.44 mg/day) of sublingual BUP as an
adjunctive treatment.
3. Discussion
3.1. Summary of Main Findings
All the considered (13) studies concluded that BUP—alone or in co-administration with opiate
antagonists such as naloxone and samidorphan—may significantly reduce depression symptoms,
NSSI, and suicidal ideation in both TRD patients and opiate-dependent patients. Importantly,
Bodkin et al. [42] and Nyhuis et al. [46] reported some case reports regarding a complete remission
with BUP. According to the studies of Striebel and Kalapatapu [47] and Ahmadi and colleagues [52],
even considering that they are only clinical cases, a complete absence of suicidal ideation after
BUP administration has been observed. Specifically, these effects were observed after one week
of drug-treatment based on the study of Striebel and Kalapatapu [47], and after just few hours with
a single BUP administration according to the Ahmadi and colleagues’ study [52]. Other studies
including TRD patients, anyway, showed an improvement in depressive symptoms in different
percentages: about 50% in Emrich et al. [41] and Fava et al. [45], and 66.7% in Karp and colleagues [43].
Regarding the studies on opioid-dependent patients, Kosten et al. [48] found a good response in 47%
of the sample; in particular, 75% of responders showed the largest improvement during the first week
of BUP treatment. Gerra and colleagues [50] observed similar results showing a significant reduction
in the Symptom Checklist-90 (SCL-90) score of irritability, depression, tiredness, and psychosomatic
symptoms after three months of BUP 4 mg + naltrexone 50 mg. Only in one study conducted on heroine
dependent patients [49], BUP resulted as effective as methadone being associated with a significant
clinical improvement on depressive symptoms, in methadone treated patients but fewer subjects on
BUP remained depressed compared to those on methadone. However, as explained by the same
authors, the doses of methadone and BUP may not have been equivalent in this study, making group
comparisons difficult.
Overall, these results regarding the potential antidepressant activity of BUP, are in line with
existing pharmacological studies where the agonism of MORs was correlated with increases in
dopamine levels, enhancement of hedonic tone and sense of contentment, which together are
responsible of the antidepressant activity [29]. Furthermore, post-mortem studies (conducted on
depressed patients who committed suicide) revealed an increased µ-opioid receptor expression which
may refer to an endogenous endorphin insufficiency [54], and can explain, at least partially, the efficacy
of BUP on depression. Another explanation related to the antidepressant effects of BUP may be found
in its monoamine inhibition activity [55]. In addition, BUP has also been shown to block the action of k
agonists [56] and a functional k antagonism has been proposed on the basis of the results derived by
Int. J. Mol. Sci. 2018, 19, 2410 8 of 20
animal models to function therapeutically as an antidepressant compound in humans [24] (this is the
hypothesized mechanism underlying the efficacy of BUP/naltrexone combination therapy for opioid
dependence [50]).
The results on the anti-suicidal potential of BUP are instead in line with both human and
animal studies that linked suicidal behavior with both mental pain and endorphinergic control of
the separation distress system [57]. Suicidal ideation and depression may be distinct, but related,
phenomena (i.e., a reduction in depressive symptoms may accompany a reduction in suicidal ideation,
as in ketamine infusion where improvements in suicidal ideation are related to, but not completely
driven by, improvements in depression and anxiety [58]).
Regarding NSSI behavior, Norelli et al. [53] found an efficacy of BUP in reducing this behavior in
five of the six investigated patients with long histories of severe repetitive NSSI behaviors refractory to
conventional approaches. Importantly, in this study, different dosages of BUP and different treatment
periods are used: case 1: BUP/naltrexone 0.5 mg/3 mg daily for nine months; case 2: BUP alone
4 mg/die for three months; case 3: BUP 2 mg/die for seven months; case 4: neither the dose nor the
time was specified; case 5: BUP for 14 days—no indications about dosages; case 6: BUP 2–4 mg/die for
seven months. Patients showed a significant reduction in NSSI behavior and, in two cases, the rapid
improvement persisted up to one year even 12 months after discontinuation.
According to specific studies [22,45], BUP in co-administration with opiate antagonists, such as
samidorphan, are able to significantly reduce depression symptoms, NSSI, and suicidal ideation.
The combination of BUP and potent µ-opioid antagonist with high sublingual bioavailability such
as samidorphan (SAM) was initially investigated in opioid-experienced, non-depressed subjects. Later,
a study assessed the preliminary efficacy of the combination BUP/SAM at the ratios identified in the
first study as an adjunctive treatment in depressed individuals having an inadequate response to SSRIs
or serotonin–norepinephrine reuptake inhibitors (SNRIs). Overall, the agonism of µ-opioid receptors
was correlated with a consistent increase in dopamine levels, enhanced hedonic tone, and sense of
contentment, while the safety and tolerability profile of BUP/SAM was favorable. Importantly, the use
of both an opioid agonist/antagonist with opposing pharmacological action of similar magnitude,
able to exert a balanced agonist–antagonist opioid modulation, seems to be linked with a normalization
of the dysregulated/impaired opioidergic tone and may yield therapeutic benefits in major depression.
Taken together, according to the included studies, BUP has a rapid antidepressant and
anti-suicidal action: in fact, this psychoactive compound seems to act in about a week after the first
administration [41–44,46–48,52]. This rapid response resembles the time course of sleep deprivation
and electro-convulsive therapy (ECT); however, the antidepressant effects of BUP might also suggest
other mechanisms of action than that regarding current available antidepressants, for instance
the activation of endorphin release in the central nervous system similarly to what occurred after
electroconvulsive therapy (ECT) [59].
Even after ketamine treatment, which is an NMDA receptor antagonist binding to opioid µ and
sigma receptors, rapid antidepressant effects together with a rapid reduction of suicidal behavior in
depressed individuals were observed based on human studies. Similarly to ketamine, BUP may exert a
rapid neuroplastic activity (ketamine, probably through the brain-derived neurotrophic factor (BDFN),
can induce enhanced dendritic branching and synaptic receptor number and density) [7].
On the other hand, there are also studies [42,47,48,50,51] suggesting that this action is prolonged
in time up to one to three months. According to the studies conducted by Emrich et al. [41] and
Karp et al. [43], once the drug is discontinued after a short-term therapy (e.g., one week), the total
score scales assessing depressive symptoms such as HAM-D and MADRS rapidly increased, suggesting
that the improvement in depressive symptoms may require long-term BUP treatment to be sustained.
Only the study of Karp et al. [43] investigated the effect of BUP on specific cognitive functions
(i.e., inhibition control, psychomotor speed, and memory for new information) in over 50 patients
who were treated with a low-dose of BUP for two months. These cognitive domains did not worsen
during exposure to the drug. It is well known that the effective treatment of depression may be
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also associated with a general improvement of cognitive symptoms (e.g., pseudo-dementia) [60].
However, high dose opioids are linked to a worsening of cognitive functions [61], although not in
non-opioid-naïve patients [62]. In the study of Karp et al. [43], the lack of slowed (and potentially
improved) psychomotor speed, inhibition, and memory suggests that low-dose BUP does not worsen,
and may potentially improve, cognitive functions.
Based on the available evidence, there is no uniqueness associated with the better formulation
to be used, neither regarding the dosage nor the expected treatment time. Generally, three types
of preparations have been used: sublingual or intranasal BUP alone, BUP/SAM, BUP/NAL,
or BUP/naltrexone. For the latter formulation, a simultaneous administration of an opioid agonist and
antagonist, may be sufficient to normalize the dysregulated endogenous opioidergic tone in the context
of depression [44]. Additionally, this type of association—whether in a balanced ratio (i.e., 1:1, 2:2
etc.) which is associated with maximal blockade of opioid effects—can prevent the potential additive
properties of BUP [44].
Many studies [44,45,49–51] proposed the treatment with BUP in augmentation with standard
antidepressants such as SSRIs or SNRIs (or with other drugs, such as antipsychotics, benzodiazepines,
and mood stabilizers [51,52] with which the patient was usually being treated). The main used dosages
ranged from very low- (0.1–0.2 mg) to high dosages (8 mg) while in just one case—a woman with severe
opioid use disorder in comorbidity with TRD and severe suicidal behavior [47]—BUP was titrated up to
16 mg. Treatment time starts from four days and goes up to three months, and—as already highlighted
above—only in the studies where BUP was administered for a long period, the results obtained were
maintained. In particular, Kosten et al. found that depressive symptoms, in opioid-addicted patients
on BUP treatment, are consistently reduced for a month with a slight plateau in the second week.
Not all the studies included in this review analyzed the occurrence of side effects related to BUP
use but, in those who considered their possible emergence [42–46,50,51], specific side-effects were
described in the majority of patients. In line with what was expected, the most common side effects of
opiate drugs include: (1) nausea; (2) constipation; (3) sedation; (4) dizziness; (5) fatigue; (6) headache;
(7) dry mouth; and (8) hyperhidrosis. These symptoms were of mild intensity, dose dependent,
and transient (they seemed to last only for the first few days of treatment) and they may be avoided
with a slower titration. Bodkin and colleagues [42] and Gerra et al. [50] even reported some cases
of irritability, anxiety, and dysphoria, which led to drop-out from the study of implicated patients.
Withdrawal symptoms were also analyzed in the studies of Karp et al. (0.2–1.6 mg BUP for eight
weeks) [43], Fava et al. (BUP/SAM 2/2 or 8/8 mg) [45], Yovell and colleagues (0.1–0.2 mg/die BUP
for four weeks) [51] but they were not reported after one week of drug discontinuation—or later.
3.2. Main Shortcomings/Limitations
The present systematic review needs to be interpreted in the light of the following limitations.
First, most of the studies involve relatively disparate dosage regimens, questionable persistence of
antidepressant effects and mixed methods for the analysis of the data that do not allow us to conduct a
meta-analysis upon the main topic.
In addition, the short duration of the study designs of some studies [41,44,46,52] need to be
mentioned. Unfortunately, a period of one week [41,44,46], or a few days more [52], may be not
sufficient to observe the long-term efficacy or the emergence of some adverse effects related to
this agent.
Another important shortcoming is represented by the modest sample size of almost all the
samples (with the exclusion of some studies [45,50,51]) which does not allow to obtain a good statistical
significance and, hence, does not allow the generalization of the main findings. Importantly, due to the
small number of findings regarding the main topic in the investigated literature, we included in this
systematic review even three case reports, the results of which are difficult to be generalized.
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Another limitation in evaluating these studies was the heterogeneity of the clinical diagnoses
related to the included subjects. Not all studies considered samples of patients with major depression
or TRD, or even samples of patients with substance-naïve patient studies along with studies of
opioid-dependent patients who might have secondary depression (e.g., substance-induced). The study
of Yovell et al. [51] also included individuals not suffering from MDD, but from other psychiatric
conditions, such as borderline personality disorder (BPD), in which suicidal ideation was present.
In addition, the participants in the study conducted by Norelli et al. [53] showed a complex history
of severe and recurrent traumas, high rate of hospitalization, and a suboptimal response to various
combinations of medications (e.g., antipsychotic medications including clozapine, antidepressants,
mood stabilizers including lithium, valproate, and carbamazepine, benzodiazepines, α-adrenergic
and β-blockers, and the opiate antagonist naltrexone). Current diagnoses were not clearly reported
within this study, which listed several lifetime diagnoses per patient starting from those given in
the infancy (i.e., attachment disorder of childhood, oppositional defiant disorder, impulse control
disorder, conduct disorder, pervasive developmental disorder, attention deficit hyperactivity disorder,
MDD without psychotic features, depressive disorder not otherwise specified, chronic post-traumatic
stress disorder (PTSD), BPD, borderline intellectual functioning, personality disorder not otherwise
specified, schizoaffective disorder, substance abuse, anorexia and bulimia, dissociative disorder,
and paraphilia). Therefore, this group of patients appeared to be extensively heterogeneous and there
seems to be no unanimity in the interpretation of the symptoms for diagnostic purposes.
Overall, according to the myriad of clinical diagnoses, the wide-range of dosages and variable
pharmacological formulations, an adequate comparison among studies is not feasible. Finally, it should
also be noted that, except for the studies of Fava et al. [45], Yovell and colleagues [51], Ehrich et al. [44]
and Dean et al. [49], the other nine studies lacked a control group.
4. Materials and Methods
4.1. Eligibility Criteria
In order to achieve a high standard of reporting, we adopted the “Preferred Reporting Items
for Systematic Reviews and Meta-Analyses” (PRISMA) guidelines [63]. We included studies that
explicitly mentioned the association between buprenorphine AND depression (OR TRD OR refractory
depression), OR buprenorphine AND suicid* (including suicidal ideation OR suicidal thoughts OR
suicide attempts), in clinical samples. We also included three studies that investigated depression
in opiate dependent patients (secondarily exploring the efficacy of BUP on depressive symptoms).
We excluded studies that explicitly investigated the use of BUP as an analgesic compound. When a
title or abstract seemed to describe a study eligible for inclusion, the full-text article was obtained
and carefully examined by a senior author (GS) to assess its relevance for the inclusion in our review.
Specifically, our exclusion criteria were as follows: (1) studies published before 1980; (2) studies without
abstracts or with abstracts that did not explicitly mention the association between depression/suicidal
behavior and BUP; (3) studies that were not published in English; and (4) systematic reviews or
meta-analytic studies regarding the main topic.
4.2. Information Sources
We conducted a systematic search of two major electronic databases comprising medical and
social science studies (PubMed and Scopus were used, while we did not search Psychinfo because
the search did not produce any consistent results concerning the main topic, and Science Direct was
not used in order to reduce redundancy) for titles and abstracts (January 1980–June 2018) relevant for
our research question. We additionally reviewed bibliographies from retrieved articles for additional
papers that might be relevant to explore the main topic of this research.
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4.3. Search Terms
The following search query was used in Pubmed: “buprenorphine” AND “depression” AND
“suicid*” AND “treatment-resistant depression” AND “TRD” AND “refractory depression”.
In addition, the search query that was used in Scopus was as follows: TITLE-ABS-KEY
(buprenorphine) TITLE-ABS-KEY (suicid*) AND TITLE-ABS-KEY (depression) AND
TITLE-ABS-KEY (treatment-resistant depression) AND TITLE-ABS-KEY (refractory depression) AND
TITLE-ABS-KEY (TRD).
4.4. Selection of Studies
Articles were screened and selected in a two-step process to minimize bias. First, two independent
researchers (G.A., G.C.) conducted the literature search. Any discrepancies between the two reviewers
who, blind to each other, examined the studies for possible inclusion were solved by consultation
with the senior reviewers (G.S., M.A., H.N.). In the second phase, full-text articles that met our
inclusion criteria were retrieved and independently reviewed by other investigators (M.P., D.D.B.)
who discussed the design and characteristics of the studies to test whether the considered studies
could be included in the review. If doubts remained, the study was put on the list of those awaiting
assessment, pending acquisition of more information, and was then carefully re-analyzed for possible
inclusion. Any disagreements in this step were solved by discussion between reviewers.
4.5. Data Collection Process
A data extraction document was developed. Overall, G.A. and G.C. independently extracted
the following data elements from the 13 studies included of this review (see ‘study sample’ below):
author(s) and publication year, presence/absence of a control group, psychiatric diagnosis, study
design, sample size and characteristics, treatment type, psychometric instruments, inter-reliability test,
limitations, main conclusions (for more details, see Tables 1–4). Reviewers acquired the full-text of all
the 13 included articles. The principal reviewers (G.S., M.A., H.N.) analyzed independently all the
studies and the other investigators (M.P., D.D.B.) finally reviewed the included documents.
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Table 1. Summary of the most relevant case-report studies concerning BUP and depression/suicidal behavior included in the present review.
Reference ControlGroup Diagnosis
Study
Design Sample Treatment
Psychometric
Instruments
Inter-Reliability
Test Limitations Main Conclusions Statistical Analyses
Quality
Assessment
Norelli et al.,
2013 [53] No
Treatment
resistant NSSI Case-report 6 adults
Personalized
doses of
buprenorphine.
No
instruments
were used for
different
amounts
of time
No
Short duration of the
clinical study; small
number of the
evaluated subjects;
lack of control
group; exiguity of
the experimental
group; lack of
exclusion criteria.
Five patients had a
significant reduction
in total incidents,
seclusion and
restraint episodes,
NSSI and improved
mood states. One
patient had not
statistically
significant changes.
A comparison was made
between the mean monthly
number of overall incidents,
NSSI episodes, and S/R
episodes without
buprenorphine treatment,
and the average number with
buprenorphine treatment. A
t-test comparison was used to
determine the significance of
the differences between these
two data sets. A t-value was
calculated for the overall
combined data from all
patients, and each individual
patient in the study. A t-value
was calculated by dividing
the overall increase or
decrease from the baseline
over the standard deviation of
post-treatment data divided
by the square root of the
number of post-treatment
data points.
I = 0; II = 0
III = 2; IV = 0
V = 0; VI = 0
Total score = 2
Striebel and
Kalapatapu,
2014 [47]
No
Chronic suicidal
ideation;
TRD;
Chronic back
pain;
Opioid
dependence
Case-report 1 adult
16/4 mg of
buprenorphine/
naloxone;
3 month.
No
instruments
were used
No
Small number of the
evaluated subjects;
lack of control
group; lack of
exclusion criteria;
lack of standardized
measures.
The patient showed
a reduction and
cessation of suicidal
thoughts and
depression and a
decrease of pain.
-
I = 0; II = 0
III = 1; IV = 0
V = 0; VI = 0
Total score = 1
Ahmadi et al.,
2017 [52] No
Chronic suicidal
ideation due to
substance-induced
depressive disorder
Case-report 25-year oldman
8-mg single
dose of
sublingual
buprenorphine;
10 days.
BSIS; BDI No
Short duration of the
clinical study; small
number of the
evaluated subjects;
lack of control
group; exiguity of
the experimental
group; lack of
exclusion criteria.
The patient had a
rapid reduction and
cessation of suicidal
thoughts
and depression.
-
I = 0; II = 0
III = 1; IV = 2
V = 0; VI = 0
Total score = 3
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Table 2. Summary of the most relevant prospective studies concerning BUP and depression/suicidal behavior included in the present review.
Reference ControlGroup Diagnosis Study Design Sample Treatment
Psychometric
Instruments
Inter-Reliability
Test Limitations Main Conclusions
Statistical
Analyses
Quality
Assessment
Kosten et al.,
1990 [48] No
Opioid
addiction
Observational
prospective study 40 adults
Buprenorphine
3.2 mg, with a range
from 2 to 8 mg;
1 month.
BDI; SDS No
Short duration of the clinical
study; lack of control group;
exiguity of the experimental
group; diagnostic
heterogeneity of the study
population.
Depression was not a primary
outcome; self-report
measures; lack of control
group; short duration of the
clinical study.
Depressive patients had a
significant reduction in
depressive symptoms at the
end of the first week; this
reduction continued over the
second week.
Depressive symptoms
steadily declined during
the month.
ANOVA
I = 2; II = 0
III = 1; IV = 1
V = 0; VI = 0
Total score = 2
Gerra et al.,
2006 [50] Yes
Opioid
dependence
Controlled
observational
prospective study
60 adults
30 patients:
naltrexone alone; 30
patients: naltrexone
(50 mg oral dose)
plus buprenorphine
(4 mg sublingual);
12 weeks.
SCL-90; VAS
for craving
scores
No
Lack of randomization; lack
of placebo buprenorphine
control; diagnostic
heterogeneity of the study
population; lack of
psychiatric evaluation at
baseline; depression not as
the primary outcome; SCL-90
is not specific for depression;
lack of exclusion criteria; for
psychopathological
evaluations only self-report
instruments were used; short
duration of the clinical study.
Patients in the naltrexone
plus buprenorphine group
showed a greater reduction in
irritability, depression,
tiredness, psychosomatic
symptoms and craving scores
than patients in the
naltrexone group.
Patients of both groups
showed a significant decrease
of irritability, depression,
tiredness and psychosomatic
symptoms scores.
ANOVA;
Kaplan-Meier;
chi-square test.
I = 2; II = 1
III = 1; IV = 1
V = 0; VI = 0
Total score = 5
Nyhuis et al.,
2008 [46] No TRD
Observational
prospective study 6 adults
Buprenorphine
ranging from 0.8 to
2.0 mg;
7 days.
HAM-D; BDI No
Short duration of the clinical
study; lack of control group;
exiguity of the experimental
group; lack of
exclusion criteria.
All six depressive patients
improved over one week;
five patients reached a
complete remission
-
I = 1; II = 0
III = 1; IV = 2
V = 0; VI = 0
Total score = 4
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Table 3. Summary of the most relevant open label non-controlled clinical trials concerning BUP and depression/suicidal behavior included in the present review.
Reference ControlGroup Diagnosis Study Design Sample Treatment
Psychometric
Instruments
Inter-Reliability
Test Limitations Main Conclusions
Statistical
Analyses
Quality
Assessment
Bodkin et al.,
1994 [42] No TRD
Open label
clinical trial,
case report
10 adults
Buprenorphine.
Dosage was titrated
according to
tolerance and
clinical benefit, with
a maximum daily
dosage of 1.8 mg;
4-6 weeks.
HAM-D; ADDS;
POMS; GAS No
Short duration of the clinical
study; small number of the
evaluated subjects; lack of
control group, exiguity of the
experimental group.
Patients showed a clinically
striking improvement in both
subjective and objective
measures of depression.
Four patients achieved a
complete remission of
symptoms, two were
moderately improved, and
one deteriorated.
Paired t-tests.
I = 1; II = 0
III = 1; IV = 2
V = 0; VI = 0
Total score = 4
Karp et al.,
2014 [43] No TRD
Open label
clinical trial
15 adults
aged 50
and older
Buprenorphine
(from 0.2 mg to 1.6
mg/day). The
average daily dose
was 0.40 mg/day;
8 weeks.
MADRS; SCID;
BSI-anxiety; the
Positive and
Negative Affect
Scales; SSI; Choice
Reaction Time Task
Congruous vs.
Incongruous
Conditions Reaction
Time Task; HVLT-R;
UKU; FIBSER; SF-26;
PSQI; COWS; MMSE
No
Lack of control group;
exiguity of the experimental
group; lack of randomization;
short duration of the
clinical study.
Patients exhibited a sharp
decline in depression severity
during the first 3 weeks, in
particular in pessimism and
sadness scores.
Executive function and
learning improved from pre-
to post-treatment.
Descriptive
analysis; Exact
Wilcoxon tests.
I = 1; II = 0
III = 1; IV = 2
V = 0; VI = 0
Total score = 4
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Table 4. Summary of the most relevant randomized, double-blind, placebo-controlled clinical trials concerning BUP and depression/suicidal behavior included in the
present review.
Reference ControlGroup Diagnosis Study Design Sample Treatment
Psychometric
Instruments
Inter-Reliability
Test Limitations Main Conclusions Statistical Analyses
Quality
Assessment
Emrich et al.,
1982 [41] Yes TRD
Double-blind,
placebo-controlled
clinical trial
10
adults
Buprenorphine 2 mg per day;
4–8 days.
HAM-D;
IMPS; VBS No
Short duration of the
clinical study; lack of
control group;
exiguity of the
experimental group.
Overall, four patients
showed more than
50% reduction in
depression, two
patients showed a
moderate response,
and four, a
slight reduction.
Wilcoxon-test.
I = 1; II = 1
III = 1; IV = 2
V = 0; VI = 0
Total score = 5
Dean et al.,
2004 [49] Yes
Heroin-
dependence
Randomized,
double-blind,
placebo
controlled
clinical trial
147
adults
68 patients: buprenorphine
sublingual tablets and
placebo methadone syrup; 79
patients: methadone syrup
and placebo buprenorphine
tablet. Dosing was initiated at
30 mg methadone or 4 mg
buprenorphine; doses were
individually titrated to
optimize response; 3 months.
BDI No
Diagnostic
heterogeneity of the
study population;
self-scored
questionnaires; lack of
psychiatric evaluation
at baseline; depression
not as the primary
outcome; lack of
exclusion criteria.
Depressive symptoms
improved in all
subjects, with no
difference between
methadone and
buprenorphine groups.
t-tests; chi-square tests.
Treatment effects data
were analyzed using a
two-way fixed effects
analysis of variance.
Outcome predictors were
examined using
regression analyses.
I = 2; II = 2
III = 1; IV = 1
V = 0; VI = 0
Total score = 6
Ehrich et al.,
2015 [44] Yes
MDD and
inadequate
response to
standard
antidepressant
therapy (TRD)
Randomized,
double-blind,
placebo
controlled
clinical trial
32
adults
14 patients: buprenorphine:
samidorphan 8:1 dose-ratio;
14 patients: buprenorphine:
samidorphan 1:1 dose-ratio; 4
patients: placebo; 1 week.
HAM-D;
MADRS;
VAS
No
Short duration of the
clinical study; small
number of the
evaluated subjects;
VAS not validated in
this population; for
psychopathological
evaluations only
self-report
instruments
were used.
Patients in the 1:1 ratio
group in seven days
exhibited statistically
significant
improvement in
depressive symptoms;
antidepressant effects
were greatest in
this group.
Descriptive statistics
about safety, t-test;
Bonferroni adjustment;
Exact Wilcoxon tests.
I = 1; II = 1
III = 1; IV = 1
V = 0; VI = 0
Total score = 4
Yovell et al.,
2016 [51] Yes
Clinically
significant
suicidal
ideation
Randomized,
double blind,
placebo-controlled
clinical trial
88
adults
57 patients: buprenorphine
(0.1 or 0.2 mg/day. Once a
week, the daily dose could be
raised of 0.1–0.2 mg
increments); 31 patients:
placebo; 4 weeks.
BSSI; BDI;
SPS No
Self-scored
questionnaires;
diagnostic
heterogeneity of the
study population.
Patients in the
buprenorphine group
had a greater
reduction in suicidal
ideation, suicide
probability and
depression scores than
patients in
placebo group.
Two-sided t tests for
continuous variables and
Pearson’s chi-square test
or
Fisher’s exact test, as
appropriate, for
categorical variables.
Correlations were
calculated using
Pearson’sr. Fisher’s r-to-z
transformation was used
for testing the difference
between correlations.
I = 2; II = 1
III = 1; IV = 1;
V = 0; VI = 0
Total score = 5
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Table 4. Cont.
Reference ControlGroup Diagnosis Study Design Sample Treatment
Psychometric
Instruments
Inter-Reliability
Test Limitations Main Conclusions Statistical Analyses
Quality
Assessment
Fava et al.,
2016 [45] Yes
MDD adults
who had an
inadequate
response to
one or two
courses of
antidepressant
treatment (TRD)
Randomized,
double-blind,
placebo-controlled
trial
142
adults
Buprenorphine/samidorphan
2 mg/2 mg;
buprenorphine/samidorphan
8 mg/8 mg; placebo; 4 weeks.
HAM-D;
MADRS;
CGI-S
Yes Short duration of theclinical study.
Patients in the 2:2 ratio
group, compared with
patients in the placebo
group, showed
significantly greater
improvements. There
was also evidence of
improvement in the
8:8 ratio group
although it did not
achieve
statistical significance.
The primary efficacy
endpoint, was evaluated
using the weighted
combination of statistics
from the stage-specific
mixed models for
repeated measures
(MMRM); Kenward-Roger
approximation was used
to adjust the denominator
degrees of freedom.
Combined inference was
conducted using the
weighted linear
combination of stage-wise
test statistics.
I = 2; II = 2
III = 1; IV = 2
V = 2; VI = 2
Total score = 11
Abbreviations: MDD = Major Depressive Disorder; TRD = Treatment-Resistant Depression; BD = Bipolar Disorder; MADRS= Montgomery–Åsberg Depression Rating Scale; SCID-I =
Structured Clinical Interview for DSM; BDI = Beck Depression Inventory; BSSI = Beck Scale for Suicidal Ideation; HAM-D = Hamilton Rating Scale for Depression; SCL-90 = Symptom
Checklist-90; VAS = Visual Analogue Scale; BSI-Anxiety = Brief Symptom Inventory—Anxiety Subscale; UKU = Udvalg for Kliniske Undersogelser Side Effects Rating Scale; SF-36 = Short
Form 36; FISBER = Burden of Side Effects Rating; PSQI = Pittsburgh Sleep Quality Index; COWS = Clinical Opiate Withdrawal Scale; HVLT-R = Hopkins Verbal Learning Test-Revised;
MMSE = Mini Mental State Exam; SPS = Suicide Probability Scale; CESD = Center for Epidemiologic Studies Depression scale; BPI = Brief Pain Inventory; PHQ-2 = Patient Health
Questionnaire; BPI = Brief Pain Inventory; SF-36v2 = Short Form version 2; MOS-SS = Medical Outcomes Study Sleep Scale; ODI = Oswestry Disability Index; ADDS = the Atypical
Depression Diagnostic Scale; POMS = the Profile of Mood States; GAS = Global Assessment Scale; VBS = Verlaufs-Beurteilungs-Skala; CGI-S = Clinical Global Impressions severity scale;
SDS = Short Depression Scale; IMPS = Inpatient Multidimensional Psychiatric Scale; BSIS = Beck Suicide Intent Scale; NSI = Non-Suicidal Self-Injury. Quality assessment parameters:
(1) representativeness of the sample from the general population (0–2 points); (2) presence and representativeness of a control group (0–2 points); (3) presence of follow-up (0–2 points);
(4) evidence based measures to evaluate suicidal ideation or suicide attempts (e.g., Suicidal Probability Scale—SPS, Suicidal Ideation Questionnaire—SIQ, Beck Hopelessness Scale—BHS,
or other psychometric evaluations) or major depression (e.g., Montgomery Åsberg Depression Rating Scale—MADRS, Hamilton Depression Rating Scale—HDRS, or other psychometric
evaluations) or concerning TRD, the use of rating scales for staging (e.g., Thase & Rush criteria, Souery criteria, etc.) (0–2 points); (5) presence of raters who identified independently the
presence of suicidal ideation or suicide attempts or depression; (6) statistical evaluation of inter-rater reliability (0–2 points); (7) quality of the statistical analysis. Quality scores ranged
from 0 to 14. Studies were assessed regarding quality as follows: (1) good quality (9–14 points) if most or all the criteria were fulfilled, or the study conclusions were deemed very robust;
(2) moderate quality (4–8 points) whether only some criteria were fulfilled, or the study conclusions were deemed robust; and (3) low quality (0–3 points) whether few criteria were
fulfilled or the conclusions of the study were not deemed robust. Caution was exercised in interpreting the findings related to low-quality studies.
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5. Conclusions
In summary, despite the limitations mentioned above, it is possible to tentatively conclude that
BUP is an effective, well-tolerated, sufficiently safe (at low doses) compound in reducing depressive
symptoms and serious suicidal ideation, even in patients with TRD who do not respond to conventional
antidepressant medications or ECT. However, further studies, in particular concerning the long-term
efficacy and safety of this medication, need to be carried out, even due to its potential for abuse.
Given the efficacy at very low doses, BUP administration may be started at 0.1–0.2 mg daily
and—if possible—it should be recommended to slowly titrate the drug, in order to avoid its side effects
until a personalized dosage may allow a sufficient clinical response. Future studies, involving a larger
number of patients, are required to replicate the preliminary antidepressant and antisuicidal properties
of BUP.
Finally, additional studies are especially needed to test the efficacy of BUP vs. BUP + SAM vs.
BUP + NAL vs. placebo, to assess both BUP’s clinical effect as well as to evaluate the withdrawal
symptoms and the low risk of addiction with BUP at very low doses.
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